Notably, CCNA2 has been associated with aberrant cell cycle progression in several types of cancer, and has been posited as a potential therapeutic target that could be inhibited to repress cell proliferation (Ma, 2019; Yang et al., 2020). The gene discussed is CCNA2; the disease is cancer.